Post-Earnings Research - St. Jude Medical

LONDON, February 24, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge.com has issued free post-earnings research on St. Jude Medical Inc. (NYSE: STJ). On January 28, 2015, the company reported its financial results for Q4 FY14 and full year FY14 (period ended January 03, 2015). Click on http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ to read our free earnings review on St. Jude Medical Inc. (St. Jude Medical). During Q4 FY14 and full-year FY14, the company's net sales, on a constant-currency basis, grew approximately 5% Y-o-Y and 4% Y-o-Y, respectively. Additionally, non-GAAP net earnings attributable to St. Jude Medical per share increased approximately 11% Y-o-Y, on a constant currency basis, in Q4 FY14. Our free coverage report can be accessed at:

http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ

Earnings Overview 

During Q4 FY14, St. Jude Medical reported net sales of $1.44 billion compared to $1.42 billion in Q4 FY13. The company's Q4 FY14 net sales came in line with Bloomberg analysts' forecast of $1.44 billion. In Q4 FY14, St. Jude Medical's total U.S. sales increased 6% Y-o-Y, while total international sales fell 3% Y-o-Y. Free research on STJ can be downloaded in PDF format at:

http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ

In Q4 FY14, GAAP net earnings attributable to St. Jude Medical improved to $245 million, or $0.84 per diluted share, from $123 million, or $0.42 per diluted share, in Q4 FY13. Analysts from Bloomberg had expected GAAP net earnings attributable to St. Jude Medical of $269 million, or $0.92 per diluted share, in Q4 FY14. The company's non-GAAP net earnings attributable to St. Jude Medical increased to $298 million, or $1.03 per diluted share, in Q4 FY14 from $294 million, or $0.99 per diluted share, in Q4 FY13.

For FY14, St. Jude Medical's net sales were $5.62 billion compared to $5.50 billion in FY13. The company's FY14 net sales came in line with Bloomberg analysts' forecast of $5.62 billion. During FY14, GAAP net earnings attributable to St. Jude Medical improved to $1.00 billion, or $3.46 per diluted share, from $723 million, or $2.49 per diluted share, in FY13. Analysts from Bloomberg had expected GAAP net earnings attributable to St. Jude Medical of $1.03 billion, or $3.54 diluted per share, in FY14. Sign up and read the free analyst's notes on STJ at:

http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ

Chairman, President and CEO of St. Jude Medical, Daniel J. Starks, informed that the company's product portfolio positions it well and provides competitive advantage for St. Jude Medical to accelerate sales growth and drive EPS leverage on a constant currency basis in 2015.

In its guidance for Q1 FY15, St. Jude Medical expects revenue to grow in the range of 2% to 4% on a constant currency basis, with negative currency impacting the quarter's revenue by approximately $85 million to $100 million. For full-year FY15, the company anticipates total revenue to grow in the range of 3% to 5%, on a constant currency basis, with negative currency impacting the revenue by approximately $325 million to $350 million. Further, the company expects consolidated adjusted earnings per share to be in the range of $0.90 and $0.92 for Q1 FY15 and of between $3.95 and $4.00 for full-year FY15 respectively. Visit Investor-Edge and access the latest research on STJ at:

http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ

Stock Performance 

On the day of the earnings release, January 28, 2015, St. Jude Medical stock gained 1.14% finishing the session at $67.39. Since then, the stock has moved both ways with gains outperforming losses. On the last close, Monday, February 23, 2015, the company's shares finished 0.40% higher at $68.55. The company's shares vacillated between $68.01 and $68.82 during the session. A total of 1.53 million shares were traded which was below its three months average volume of 2.08 million shares. Over the previous three trading sessions and last one month, St. Jude Medical shares have gained 1.95% and 5.48%, respectively. Further, the stock has advanced 2.62% over the past three months. Shares in the company closed above their 50-day and 200-day moving averages of $66.36 and $65.28, respectively. Furthermore, the stock traded at a PE ratio of 17.43.

Sneak Peek to Corporate Insider Trading 

In the last one month, there were 36 corporate insider transactions made by 11 individuals. Between January 28, 2015, and February 16, 2015, a total of 257,305 shares have been purchased at an average price of $40.13 per share and for a total value of $10.33 million. During the same period, a total of 249,739 shares, worth $16.61 million, were sold at an average price of $66.51 per share. The following are a few of the aforementioned transactions: on January 30, 2015, Joel D. Becker, President- Americas Division at St. Jude Medical, bought 37,916 shares at an average price of $35.13 per share and disposed 47,683 shares at an average price of $65.86 per share; on February 03, 2015, Denis M. Gestin, President International Division at St. Jude Medical, purchased 148,500 shares at an average price of $36.30 per share and disposed an equal number of shares at a price of $67.13 per share; on February 16, 2015, Paul Bae, Vice President Global Human Resources and Chief Compliance Officer at St. Jude Medical, bought 28,240 shares at a price of $67.48 per share. Complimentary in-depth research on STJ is available at:

http://get.Investor-Edge.com/pdf/?c=St.%20Jude%20Medical&d=24-Feb-2015&s=STJ

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge